Giving

Department of Oncology

Cumming School of Medicine, University of Calgary 

In partnership with Arnie Charbonneau Cancer Institute

Department of Oncology

Cumming School of Medicine, University of Calgary 

In partnership with Arne Charbonneau Cancer Institute

Balogh, Alex

Radiation Oncology

Clinical Associate Professor

EMAIL: alex.balogh@ahs.ca

Biography

Dr. Balogh received his MD from Queen’s University in 1993. He completed his residency in 1998 at the University of Toronto (Princess Margaret Hospital/Odette Cancer Centre) and University of Western Ontario (London Regional Cancer Centre). He completed his fellowship in GU and Lymphoma in 1999 at the University of Western Ontario (LRCC). He has been on staff at the Tom Baker Cancer Centre since April 1999. Dr. Balogh was the residency program director from its inception in 1990 until September 2006. He has been the principal investigator for the RTOG/NRG since 2007. He is a member of ILROG (The International Lymphoma Radiation Oncology Group). Dr. Balogh is presently a member of the GU and lymphoma (hematology) tumor groups. His GU interests include post prostatectomy radiation, and radiation of penile cancer. His hematology interests include TBI (total body irradiation) for stem cell transplants in hematologic malignancies as well as the optimal use of radiation in leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and myeloma. He has multiple publications in the GU field with RTOG/NRG and multiple publications in the hematology field with ILROG.

Area of Focus

Summary of Research

  1. Binkley M, Rauf MS, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel NG, Hoppe B, Terezakis S, Picardi M, Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood. 2020 Jun 25;135(26):2365-2374.
  2. Frederick Rebecca, Hudson Alana, Balogh Alex, Cao Jeffrey Q., Pierce Greg. Standardized Flattening Filter Free Volumetric Modulated Arc Therapy Plans Based on Anteroposterior Width for Total Body Irradiation. J Appl Clin Med Phys 2020; 21:3:75-86 (refinement of technique)
  3. Brady J, Binkley M, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi A, Jones M, Manus M, Wirth A, Oguchi M, Vistisen A, Andraos T, Ng A, Aleman B, Choi S, Kirova Y, Hardy S, Reinhartz G, Eich H, Bratman S, Constine L, Suh CO, Dabaja B, El-Galay T, Hodgson D, Ricardi U, Yahalom J, Hoppe R, Mikhaeel NG. Definitive Radiotherapy for Localized Follicular Lymphoma Staged by 18F-FDG PET-CT: a Collaborative Study by ILROG. Blood 2019; 133(3) 237-245 (second largest contributor to study)
  4. Michael S. Binkley, MD, MS,* Jessica L. Brady, MBBCh, FRCR, Carla Hajj, MD, Monica Chelius, BA, Karen Chau, BA, Alex Balogh, MD, Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG International Journal of Radiation Oncology • Biology • Physics, 2019 Jul 1;104(3):522-529. doi: 10.1016/j.ijrobp.2019.03.004 (Second Largest Contributor to Study; Published March 8, 2019)
  5. Seth A. Rosenthal, Chen Hu, Oliver Sartor, Leonard G. Gomella, Mahul B. Amin, James Purdy, Jeff M. Michalski, Mark G. Garzotto, Nadeem Pervez, Alexander G. Balogh, George B. Rodrigues, Luis Souhami, M. Neil Reaume, Scott G. Williams, Raquibul Hannan, MD, Eric M. Horwitz, Adam Raben, Christopher A. Peters, Felix Y. Feng,  William U. Shipley, and Howard M. Sandler, Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: RTOG 0521 JCO 2019 Mar 12; 37(14):1159-1168 (practice changing)
  6. Pierce G, Balogh A, Frederick R, Gordon D, Yarschenko A, Hudson A. Extended SSD VMAT treatment for total body irradiation. J Appl Clin Med Phys. 2019 Jan: 20(1):200-211. (new technique)
  7. Nichols C, Hu C, Bahary JP, Zeitzer K, Souhami L, Leibenhaut M, Rotman M, Gore E, Balogh A, McGowan D, Michalski J, Raben A, Rudoler S, Jones C, Sandler H. Serum Testosterone Changes in Patients Treated with Radiation Therapy Alone for Prostate Cancer on NRG Oncology RTOG 9408. Advan Rad Oncol. 2017;2:608-614
  8. Shipley W, Seiferheld W, Lukka H, Major P, Heney N, Grigon D, Sartor O, Patel M, Bahary J, Zietman A, Pisansky T, Zeiter K, Lawton C, Feng F, Lovett R, Balogh A, Souhami L, Rosenthal S, Kerlin K, Dignam J, Pugh S, Sandler H. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. New Eng J Med. 2017;376(5):417-428. (RTOG 96-01) (practice changing)
  9. Mak R, Hunt D, Efstathiou K, Heney N, Jones C, Lukka H, Bahary JP, Patel M, Balogh A, Nabid A, Leibenhaut M, Hamstra D, Roof K, Lee RJ, Gore E, Sandler H, Shipley W. Acute and Late Urinary Toxicity Following Radiation in Men with an Intact Prostate Gland or after a Radical Prostatectomy: A Secondary Analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016;34:430.e1-430.e7
  10. Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider M, Duclos M, Rosenthal S, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ,  Sandler H. Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer – Radiation Therapy Oncology Group Randomized Trial 9910. J Clin Oncol. 2015;33:332-339

Area Of Focus

Summary Of Research

  1. Binkley M, Rauf MS, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel NG, Hoppe B, Terezakis S, Picardi M, Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood. 2020 Jun 25;135(26):2365-2374.
  2. Frederick Rebecca, Hudson Alana, Balogh Alex, Cao Jeffrey Q., Pierce Greg. Standardized Flattening Filter Free Volumetric Modulated Arc Therapy Plans Based on Anteroposterior Width for Total Body Irradiation. J Appl Clin Med Phys 2020; 21:3:75-86 (refinement of technique)
  3. Brady J, Binkley M, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi A, Jones M, Manus M, Wirth A, Oguchi M, Vistisen A, Andraos T, Ng A, Aleman B, Choi S, Kirova Y, Hardy S, Reinhartz G, Eich H, Bratman S, Constine L, Suh CO, Dabaja B, El-Galay T, Hodgson D, Ricardi U, Yahalom J, Hoppe R, Mikhaeel NG. Definitive Radiotherapy for Localized Follicular Lymphoma Staged by 18F-FDG PET-CT: a Collaborative Study by ILROG. Blood 2019; 133(3) 237-245 (second largest contributor to study)
  4. Michael S. Binkley, MD, MS,* Jessica L. Brady, MBBCh, FRCR, Carla Hajj, MD, Monica Chelius, BA, Karen Chau, BA, Alex Balogh, MD, Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG International Journal of Radiation Oncology • Biology • Physics, 2019 Jul 1;104(3):522-529. doi: 10.1016/j.ijrobp.2019.03.004 (Second Largest Contributor to Study; Published March 8, 2019)
  5. Seth A. Rosenthal, Chen Hu, Oliver Sartor, Leonard G. Gomella, Mahul B. Amin, James Purdy, Jeff M. Michalski, Mark G. Garzotto, Nadeem Pervez, Alexander G. Balogh, George B. Rodrigues, Luis Souhami, M. Neil Reaume, Scott G. Williams, Raquibul Hannan, MD, Eric M. Horwitz, Adam Raben, Christopher A. Peters, Felix Y. Feng,  William U. Shipley, and Howard M. Sandler, Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: RTOG 0521 JCO 2019 Mar 12; 37(14):1159-1168 (practice changing)
  6. Pierce G, Balogh A, Frederick R, Gordon D, Yarschenko A, Hudson A. Extended SSD VMAT treatment for total body irradiation. J Appl Clin Med Phys. 2019 Jan: 20(1):200-211. (new technique)
  7. Nichols C, Hu C, Bahary JP, Zeitzer K, Souhami L, Leibenhaut M, Rotman M, Gore E, Balogh A, McGowan D, Michalski J, Raben A, Rudoler S, Jones C, Sandler H. Serum Testosterone Changes in Patients Treated with Radiation Therapy Alone for Prostate Cancer on NRG Oncology RTOG 9408. Advan Rad Oncol. 2017;2:608-614
  8. Shipley W, Seiferheld W, Lukka H, Major P, Heney N, Grigon D, Sartor O, Patel M, Bahary J, Zietman A, Pisansky T, Zeiter K, Lawton C, Feng F, Lovett R, Balogh A, Souhami L, Rosenthal S, Kerlin K, Dignam J, Pugh S, Sandler H. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. New Eng J Med. 2017;376(5):417-428. (RTOG 96-01) (practice changing)
  9. Mak R, Hunt D, Efstathiou K, Heney N, Jones C, Lukka H, Bahary JP, Patel M, Balogh A, Nabid A, Leibenhaut M, Hamstra D, Roof K, Lee RJ, Gore E, Sandler H, Shipley W. Acute and Late Urinary Toxicity Following Radiation in Men with an Intact Prostate Gland or after a Radical Prostatectomy: A Secondary Analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016;34:430.e1-430.e7
  10. Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider M, Duclos M, Rosenthal S, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ,  Sandler H. Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer – Radiation Therapy Oncology Group Randomized Trial 9910. J Clin Oncol. 2015;33:332-339
© Department of Oncology

Contact Us

DEPARTMENT OF ONCOLOGY

TOM BAKER CANCER CENTRE

1331 29th STREET NW CALGARY AB CANADA T2N 4N2

Links